Diarrhea in chronic inflammatory bowel diseases.
Diarrhea is a common clinical feature of inflammatory bowel diseases and may be accompanied by abdominal pain, urgency, and fecal incontinence. The pathophysiology of diarrhea in these diseases is complex, but defective absorption of salt and water by the inflamed bowel is the most important mechanism involved. In addition to inflammation secondary to the disease, diarrhea may arise from a variety of other conditions. It is important to differentiate the pathophysiologic mechanisms involved in the diarrhea in the individual patient to provide the appropriate therapy. This article reviews microscopic colitis, ulcerative colitis, and Crohn's disease, focusing on diarrhea.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. heimo.wenzl@klinikum-graz.at
Heimo H
HH
Wenzl
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D001706:Biopsy; D001729:Bismuth / Q000627:therapeutic use; D001772:Blood Cell Count; D001774:Blood Chemical Analysis; D001834:Body Water / Q000378:metabolism; D001944:Breath Tests; D019819:Budesonide / Q000627:therapeutic use; D002792:Cholestyramine Resin / Q000627:therapeutic use; D046728:Colitis, Microscopic / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology*; D064420:Drug-Related Side Effects and Adverse Reactions; D016099:Endoscopy, Gastrointestinal; D005243:Feces / Q000737:chemistry; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000150:complications* / Q000175:diagnosis; D007408:Intestinal Absorption / Q000502:physiology; D007412:Intestinal Fistula / Q000150:complications; D007413:Intestinal Mucosa / Q000473:pathology; D007422:Intestines / Q000382:microbiology / Q000601:surgery; D017136:Ion Transport; D008286:Malabsorption Syndromes / Q000150:complications; D008487:Medical History Taking; D019804:Mesalamine / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D010808:Physical Examination; D011183:Postoperative Complications; D011239:Prednisolone / Q000627:therapeutic use; D012459:Salicylates / Q000627:therapeutic use; D012964:Sodium / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000930:Antidiarrheals; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D009942:Organometallic Compounds; D012459:Salicylates; D014409:Tumor Necrosis Factor-alpha; D002792:Cholestyramine Resin; D019804:Mesalamine; D019819:Budesonide; C015715:bismuth subsalicylate; D012964:Sodium; D011239:Prednisolone; D001729:Bismuth